Germany's Merck nears roughly $3.5 billion deal for SpringWorks, WSJ reports
April 24 (Reuters) - Germany's Merck KGaA MRCG.DE is nearing a roughly $3.5 billion deal for SpringWorks Therapeutics SWTX.O, the Wall Street Journal reported on Thursday, citing people familiar with the matter. (Reporting by Sriparna Roy in Bengaluru; Editing by Alan Barona) ((Sriparna.Roy@thomsonreuters.com))
Recent news on SpringWorks Therapeutics
See all newsBrief: Merck KGaA Completes Acquisition Of Springworks Therapeutics
Brief: Springworks Therapeutics Expects Nirogacestat Decision From European Commission In Q3
Brief: EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN